What is tirzepatide?
Tirzepatide activates two gut-hormone receptors at once — GLP-1 and GIP — which is why researchers call it a dual agonist and why it has drawn so much attention in weight and metabolic research.
This page collects everything we've written about it: how it works, dosing and titration, side effects, comparisons with semaglutide, and what compounded tirzepatide involves. Compounded tirzepatide is available only by prescription; a licensed provider reviews every request, and not everyone qualifies. Start with the mechanism article if you're new — the rest builds on it.
100 articles on this topic
-
Should I Take Tirzepatide? How a Provider Decides
Should I take tirzepatide? It may fit when weight is affecting health, but a BMI number alone cannot answer the question. A provider weighs the goal, medical history, past GLP-1 experience and practical access together.
-
SURMOUNT-2 Results: What the Trial Found
SURMOUNT-2 followed 938 adults with obesity or overweight and type 2 diabetes for 72 weeks. Average weight change was -12.8% and -14.7% with tirzepatide, compared with -3.2% with placebo.
-
Does Tirzepatide Cause Low Blood Sugar?
Tirzepatide can cause low blood sugar, but it was uncommon in trials of people without diabetes. The risk rises when insulin or a sulfonylurea is also part of treatment.
-
What Is an IND? A Plain-English FDA Guide
An IND is the filing that lets a sponsor begin testing an investigational drug in people. It opens a research path, not a sales or prescription path.
-
5 Percent Weight Loss Benefits: Study Numbers
Five percent can be a meaningful first milestone. Here's what studies measured in blood sugar, blood pressure, and sleep, and where the numbers stop being a useful prediction.
-
Does Semaglutide Cause Headaches? The Facts
Headache is a recognized side effect, but the timing alone doesn't explain it. The trial rates, possible triggers, and symptoms that need prompt care.
-
SELECT Trial Semaglutide Results: What 20% Means
SELECT recorded fewer major heart and blood-vessel events with branded semaglutide. Here is what the 20% headline means, who was studied, and where the evidence stops.
-
Semaglutide and Antidepressants: Can They Mix?
An antidepressant alone does not rule out semaglutide. The useful questions are how tablets are absorbed, how mood is doing, and what each medicine means for weight.
-
Should I Take Semaglutide? How a Provider Decides
A BMI of 32 can open the conversation. Medical history, current medicines and a workable follow-up plan determine where it goes.
-
FDA Category 2 Bulk Drug Substances: What It Means
Category 2 means FDA has identified significant safety concerns about a nominated compounding ingredient. Here is what the category tells a patient, and why leaving it does not mean approval.
-
STEP 1 Trial Results: What the 14.9% Average Means
The 68-week semaglutide study found 14.9% average weight loss versus 2.4% with placebo. The details show who was studied, who stopped treatment and what happened later.
-
Tirzepatide and Kidney Disease: Risks and Evidence
Kidney disease does not automatically rule out tirzepatide. The key questions are dehydration risk, recent kidney tests and what the newer studies actually measured.
-
TrumpRx GLP-1 Prices: Beyond the Starting Price
Wegovy pills start at $149 and some pen offers at $199. Later fills, strength and eligibility determine the bill that follows.
-
503B Outsourcing Facility: What the Term Means
A 503B facility can prepare compounded medicines for clinic stock under federal manufacturing rules. Its registration describes the facility, not a review of each medicine.
-
10 Questions to Ask Doctor About Tirzepatide
A tirzepatide visit is mostly about fit: the provider needs a clear picture of medical history, medicines, pregnancy plans, digestion, and upcoming procedures. These ten questions explain what matters and why.
-
SURMOUNT-1 Results: What the Trial Actually Found
SURMOUNT-1 followed 2,539 adults without diabetes for 72 weeks. Average weight change ranged from -15.0% to -20.9% with tirzepatide, compared with -3.1% with placebo.
-
15 Percent Weight Loss: What the Numbers Show
At 220 pounds, 15 percent is 33 pounds. Trials also measured waist, blood pressure, blood sugar, sleep, pain and physical function—but those group averages are not a personal forecast.
-
Who Discovered GLP-1? The Team Behind the Medicine
No single scientist discovered GLP-1. The answer is a chain of teams that found the gene, identified the working hormone, tested what it did, and designed medicines that lasted long enough to use.
-
Zepbound Prescribing Information, Explained
The current label is revised August 2026. It covers two uses, a weekly dose ladder, two absolute contraindications, the boxed thyroid warning, common stomach side effects, pregnancy, and four delivery formats.
-
FDA Tentative Approval: What It Means
FDA tentative approval means an application has cleared the scientific review needed for approval, but a legal barrier still prevents U.S. marketing. It is a real milestone, not permission to sell the drug.
Page 1 of 5 · 100 articles